EntryPoint Capital’s Avita Medical RCEL Stock Holding History

EntryPoint Capital’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,961	Closed	-$224K	–	1487
2024 Q1	$224K	Buy	+13,961	New	+$226K	0.2%	87

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EntryPoint Capital's RCEL Position: Q2 2024 in Review

EntryPoint Capital sold out of Avita Medical (RCEL) in Q2 2024, closing a stake of 13,961 shares — an estimated $224K sold.

EntryPoint Capital first reported a position in RCEL in Q1 2024 and held it in 1 quarter. The position peaked at $224K in Q1 2024. 68 funds tracked by Wall St. Rank hold RCEL as of Q2 2024.

EntryPoint Capital reported no remaining Avita Medical position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 13,961 Avita Medical shares in Q2 2024, an estimated $224K.
EntryPoint Capital first reported a position in Avita Medical in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's Avita Medical position peaked at $224K in Q1 2024.
68 funds tracked by Wall St. Rank held Avita Medical as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.